MedTrace Logo

Treatment Regimens in Meibomian Gland Dysfunction

NCT05594745 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2023-04-12

No results posted yet for this study

Summary

This study seeks to explore the relevance of inflammation in dry eye patients with MGD and compare the efficacy of LipiFlow treatment followed by lid hygiene and lubricant treatment with Systane Ultra or LipiFlow treatment followed by lid hygiene and lifitegrast treatment in patients with meibomian gland dysfunction.

Conditions

  • Dry Eye Syndromes

Interventions

DRUG

Lifitegrast Ophthalmic

eyedrop

DRUG

Systane Free

eyedrop

DEVICE

Lipiflow

thermal pulsation

Sponsors & Collaborators

  • Tauber Eye Center

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-03-02
Primary Completion
2023-01-21
Completion
2023-01-21
FDA Drug
Yes
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05594745 on ClinicalTrials.gov